BUYINS.NET: Rockwell Medical Technologies (RMTI) SqueezeTrigger Price is $6.53. Over 3.28 Million Total Shares Short Since 2005.

BUYINS.NET, www.buyins.net, is initiating coverage of Rockwell Medical Technologies (NASDAQ: RMTI) after releasing the latest short sale data to October 2009. BUYINS.NET is a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance. The report can be viewed at:

www.buyins.com/reports/rmti10-26-09.pdf

The Rockwell Medical Technologies report includes the following short sale data: Daily Short Volume, Monthly Short Volume, Naked Short Volume, Market Maker Friction Factor.

Highlights from the RMTI report:

Over 3.28 million shares of combined total short volume since 2005.

Over 115,000 shares of total short volume in one trading day in September 2009.

Market Makers bearishly-biasing RMTI market price and may violate Reg SHO rules.

SqueezeTrigger Price is $6.53.

To access SqueezeTrigger prices that short squeezes may begin, along with trading signals on all US stocks, visit http://www.buyins.net .

About Rockwell Medical Technologies: Rockwell (NASDAQ: RMTI) is a fully-integrated biopharmaceutical company offering innovative products and services initially targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia. An established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad, Rockwell provides products that are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Dialysis is a process that duplicates kidney function for patients who suffer from ESRD. There are approximately 400,000 ESRD patients in the United States growing at an annual rate of 4 percent, and approximately 2 million ESRD patients world-wide.

The Company is currently developing unique, proprietary renal drug therapies for iron treatment. These exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. A third party has paid $995 per month to purchase data for information provided in twelve monthly reports. The data service can be cancelled at any time. The third party or its affiliates may own shares of RMTI and can benefit from a rise in the share price. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Rockwell's SEC filings. Thus, actual results could be materially different. Rockwell expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT: Thomas Ronk, CEO, BUYINS.NET WWW: http://www.buyins.net e-mail: tom@buyins.net Tel: +1 800 715 9999

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: advisor, anemia, broker, ceo, dealer, disease, earnings, e-mail, hedge fund, investment, investment opinion, law, manufacturer, market, medical, nasdaq, pipeline, prices, products, sales, sec, securities, statistics, technology, web